Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
This Surgical Robot Could Transform the Operating Room
02.08.2026 12:08
After spending years and hundreds of millions of dollars, Johnson and Johnson has won FDA approval for its new surgical robot Ottava. Can it challenge the dominance of competitors who entered the race years earlier, or is the market already spoken for?
J&J’s biotech progress could punish its 2027 profit
01.08.2026 01:03
Johnson & Johnson (JNJ) just issued one of the weirdest profit warnings in health care. The biotech business decreased its 2026 adjusted earnings guidance to between $10.96 and $11.11 a share, from a range of $11.60 to $11.75. This year, the newly closed acquisition of Firefly Bio and the ...
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
30.07.2026 12:30
Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). If approved, it would provide a new treatment for patients whose disease has progressed following platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Priority Review is grante
Bristol-Myers Squibb: Why I'm Still Bullish After Q2
30.07.2026 09:30
Bristol-Myers Squibb Company hits a 52-week high on Q2 results, EPS guidance raise, and key drugsâ momentum. Read why BMY stock is a buy.
Johnson & Johnson (JNJ) Seeks $5.5 Billion Talc Lawsuit Settlement
30.07.2026 00:15
Johnson & Johnson proposed a $5.5b settlement to resolve tens of thousands of ovarian cancer talc lawsuits. The offer aims to address a decade-long legal dispute involving the company’s talcum powder products. The settlement would require approval from a majority of claimants before it can move forward. For investors watching Johnson & Johnson (NYSE:JNJ), this legal development sits alongside a stock that closed at $265.53 and has recently shown strong momentum. The shares are up 3.9% over...
Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation
28.07.2026 15:26
Johnson & Johnson (NYSE:JNJ) has reached an agreement to resolve tens of thousands of lawsuits in the US alleging that its talc-based products, including its baby powder, caused ovarian cancer, with the company committing up to $5.5 billion to settle the remaining claims. The proposed...
Johnson & Johnson offers up to $5.5 billion to settle baby powder cancer lawsuits
28.07.2026 14:21
Johnson & Johnson has set aside $5.5 billion to resolve tens of thousands of US lawsuits alleging that its talcum powder-based products caused ovarian cancer.
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
28.07.2026 14:07
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
Johnson & Johnson settling talc baby powder lawsuits for $5.5 billion
28.07.2026 12:13
The deal covers about 76,000 ovarian cancer claims and requires acceptance by at least 95% of claimants to take effect
Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight
28.07.2026 12:12
Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer. The drugmaker, which has been fighting talc-related lawsuits for more than a decade, said that the settlement is conditioned on at least 95% of remaining claimants participating. A U.S. bankruptcy court judge denied a $9 billion settlement proposed by company subsidiary Red River Talc last year that would have been one of the biggest mass tort settlements in history.
Johnson & Johnson offers £4.1bn to settle talcum powder cancer claims
28.07.2026 10:17
Johnson & Johnson (J&J) has agreed to pay an estimated $5.5bn (£4.1bn) to resolve tens of thousands of claims that its baby powder caused ovarian cancer.
Johnson & Johnson reaches $5.5 billion baby powder settlement
28.07.2026 10:16
STORY: :: New York / July 27, 2026:: Dietrich Knauth, Legal Reporter"After years of litigation, about 70,000 court cases, and three bankruptcies, Johnson& Johnson has agreed to a $5.5 billion talc settlement. Why are they settling now? :: Why did J&J settle after more than a decade of talc litigation?"So tens of thousands of women have accused Johnson& Johnson of causing their ovarian cancer. They've alleged that talc-based products, including baby powder, have been contaminated with asbestos and caused them to develop cancer after using these products for a long period of time. Johnson& Johnson has denied that, but these cases have continued to go to trial.""And after a couple of attempts to settle these cases through bankruptcy courts, Johnson& Johnson has now reached a deal where they think they can end all of these cases for an overall payment that is about $5.5 billion, although that number could rise depending on how many people participate in the settlement.""One of the plaintiff's lawyers told me today that he thinks it's closer to $7 billion. That's not something we're going to know for some time.":: Could J&J still face new talc lawsuits in the future?:: Johnson & Johnson"It does not fully close the door on all future talc litigations. Somebody could develop cancer in the future, decide that they want to file a lawsuit against Johnson& Johnson, because they think that company's product caused their cancer. The reason for that is that there's something called a latency period, which is essentially the delay between when you experience the factors that caused your cancer and when that cancer actually shows up.""But, you know, this deal basically gets rid of all of the existing cases. That's the idea."J&J reached the settlement after a series of wins in court, including victories in individual trials, successful efforts to disqualify plaintiffs' lawyers from the litigation, and court rulings against experts that plaintiffs had used to prove their cases in court. J&J won a significant court victory in the long-running legal battle last week, when a federal judge cast doubt on individual plaintiffs' ability to prove that talc specifically caused their ovarian cancer.J&J has long denied that its talc products caused cancer, saying that talc was safe and did not contain asbestos. The company stopped selling talc-based baby powder in the U.S. in 2020, switching to a cornstarch product.Before the bankruptcy attempts, J&J had a mixed record in talc trials, with a multibillion verdict in favor of 22 women who said baby powder caused their ovarian cancer. The company won some trials outright and had other verdicts reduced on appeal.Unlike the proposed bankruptcy settlements, Monday's agreement applies only to existing claims and does not address future lawsuits.
Johnson & Johnson Proposes to Pay Up to $5.5 Billion to Resolve Remaining Ovarian Cancer Claims
28.07.2026 09:18
Johnson & Johnson (JNJ) has agreed to commit up to $5.5 billion to settle about 76,000 lawsuits that
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals
28.07.2026 08:58
HRMY, ACAD, BIIB, INSM and AGIO are set to report Q2 results, with positive Earnings ESPs suggesting potential earnings surprises.
Stock Market Today: Dow Jones Futures Gain as Coca-Cola Jumps After Q2 Beat, S&P 500, Nasdaq 100 Decline—Boeing, Johnson & Johnson in Focus (UPDATED)
28.07.2026 08:38
U.S. stock futures were mixed on Tuesday, as the Dow Jones and S&P 500 indices gained but Nasdaq 100 slipped, following Monday's mixed close.
Johnson & Johnson offers $5.5 billion to settle talc lawsuits
28.07.2026 06:33
Johnson & Johnson has offered $5.5 billion to settle tens of thousands of lawsuits claiming its baby powder and other talcum powder products caused ovarian cancer, the company says.
J&J offers $5.5bn to settle baby powder lawsuits
28.07.2026 04:36
Johnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer. The company said the settlement covers around 76,000 claims, having already settled most cases alleging its talc contained asbestos and caused mesothelioma. J&J's vice president of litigation, Erik Haas, said the move was motivated by a desire to get closure – describing the claims themselves as "meritless".
FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System
24.07.2026 13:31
The U.S. Food and Drug Administration on Wednesday granted De Novo authorization for Johnson & Johnson’s OTTAVA Robotic Surgical System, marking the regulatory clearance of the world’s first table-integrated soft tissue robotic platform. The marketing clearance encompasses multiple general surgery...
Jim Cramer Says Kimberly-Clark’s Acquisition of Kenvue Creates a High-Margin Powerhouse
24.07.2026 12:22
On Tuesday’s episode of CNBC’s Mad Money, Jim Cramer highlighted Kimberly-Clark Corporation (NYSE:KMB) as a defensive holding for investors looking to lock in profits from high-flying technology stocks and reallocate into lower-risk value plays. After years of sluggish price action, Cramer noted that the consumer giant has finally established a stable bottom, anchored by a […]
Legend Biotech: Why I'm Ready To Go Long Again
24.07.2026 09:45
Legend Biotech Corporation stock: strong Carvykti demand lifts Q2 sales; LB2501 CAR-T shows Phase 1 promise. Click for this LEGN update.